163 related articles for article (PubMed ID: 37796708)
41. Autoimmunity and interstitial lung disease.
Jindal SK; Agarwal R
Curr Opin Pulm Med; 2005 Sep; 11(5):438-46. PubMed ID: 16093819
[TBL] [Abstract][Full Text] [Related]
42. Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): Evolving concept of CT findings, pathology and management.
Yoo H; Hino T; Hwang J; Franks TJ; Han J; Im Y; Lee HY; Chung MP; Hatabu H; Lee KS
Eur J Radiol Open; 2022; 9():100419. PubMed ID: 35445144
[TBL] [Abstract][Full Text] [Related]
43. Management of interstitial lung disease in systemic sclerosis: lessons from SLS and FAST.
Fathi N; Furst DE; Clements PJ
Curr Rheumatol Rep; 2007 May; 9(2):144-50. PubMed ID: 17502045
[TBL] [Abstract][Full Text] [Related]
44. Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?
Herzog EL; Mathur A; Tager AM; Feghali-Bostwick C; Schneider F; Varga J
Arthritis Rheumatol; 2014 Aug; 66(8):1967-78. PubMed ID: 24838199
[No Abstract] [Full Text] [Related]
45. Resveratrol mitigates miR-212-3p mediated progression of diesel exhaust-induced pulmonary fibrosis by regulating SIRT1/FoxO3.
Singh N; Nagar E; Gautam A; Kapoor H; Arora N
Sci Total Environ; 2023 Dec; 902():166063. PubMed ID: 37544448
[TBL] [Abstract][Full Text] [Related]
46. Pulmonary fibrosis associated with rheumatoid arthritis: from pathophysiology to treatment strategies.
Diesler R; Cottin V
Expert Rev Respir Med; 2022 May; 16(5):541-553. PubMed ID: 35695895
[TBL] [Abstract][Full Text] [Related]
47. Desquamative interstitial pneumonia as the initial manifestation of systemic sclerosis.
Swartz JS; Chatterjee S; Parambil JG
J Clin Rheumatol; 2010 Sep; 16(6):284-6. PubMed ID: 20808169
[TBL] [Abstract][Full Text] [Related]
48. Relevance of immunomodulatory therapy for interstitial lung disease in systemic sclerosis.
Aringer M; Riemekasten G
Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101672. PubMed ID: 33745826
[TBL] [Abstract][Full Text] [Related]
49. Effects of Resveratrol on Pulmonary Fibrosis via TGF-β/Smad/ERK Signaling Pathway.
Liu L; Liu B; Li L; Zhou X; Li Q
Am J Chin Med; 2023; 51(3):651-676. PubMed ID: 36891982
[TBL] [Abstract][Full Text] [Related]
50. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis.
Broad K; Pope JE
Med Sci Monit; 2010 Sep; 16(9):RA187-90. PubMed ID: 20802426
[TBL] [Abstract][Full Text] [Related]
51. [How do I treat interstitial lung disease in systemic sclerosis?].
Riemekasten G
Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
[TBL] [Abstract][Full Text] [Related]
52. Atypical emphysema formation in a never-smoker with scleroderma-related interstitial pneumonia: a case report.
Jazia RB; Ayachi J; Ghzel R; Kacem A; Limem IB; Faidi A; Braiek DB; Chatbouri F; Maatallah A
Pan Afr Med J; 2022; 42():295. PubMed ID: 36415340
[TBL] [Abstract][Full Text] [Related]
53. Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ?
de Lauretis A; Veeraraghavan S; Renzoni E
Chron Respir Dis; 2011; 8(1):53-82. PubMed ID: 21339375
[TBL] [Abstract][Full Text] [Related]
54. Management of Fibrosing Interstitial Lung Diseases.
Maher TM; Wuyts W
Adv Ther; 2019 Jul; 36(7):1518-1531. PubMed ID: 31119691
[TBL] [Abstract][Full Text] [Related]
55. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies.
Nannini C; West CP; Erwin PJ; Matteson EL
Arthritis Res Ther; 2008; 10(5):R124. PubMed ID: 18937831
[TBL] [Abstract][Full Text] [Related]
56. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
Yamasaki Y; Kuwana M
Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
[TBL] [Abstract][Full Text] [Related]
57. Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus.
Moazedi-Fuerst FC; Kielhauser S; Brickmann K; Tripolt N; Meilinger M; Lufti A; Graninger W
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S87-91. PubMed ID: 25665185
[TBL] [Abstract][Full Text] [Related]
58. [Management of patients with pulmonary fibrosis].
Bestaev DV; Karateev DE; Nasonov EL
Klin Med (Mosk); 2014; 92(2):15-23. PubMed ID: 25269176
[TBL] [Abstract][Full Text] [Related]
59. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
Kuwana M; Azuma A
Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
[TBL] [Abstract][Full Text] [Related]
60. [Systemic sclerosis].
Schinke S; Riemekasten G
Internist (Berl); 2019 Dec; 60(12):1251-1269. PubMed ID: 31754753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
